Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

Design and synthesis of a novel class EGFR/HER2 dual inhibitors containing tricyclic oxazine fused quinazolines scaffold

(2020) Min Sun et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

In vivo efficacy studies of novel quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors, in lung cancer xenografts (NCI-H1975) mice models

(2020) Debasis Das et al.   BIOORGANIC CHEMISTRY

Design, synthesis and anticancer evaluation of thieno[2,3-d]pyrimidine derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers

(2019) Souad A. Elmetwally et al.   BIOORGANIC CHEMISTRY

Design, synthesis and biological evaluation of a new series of thiazolyl-pyrazolines as dual EGFR and HER2 inhibitors

(2019) Belgin Sever et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Synthesis, cytotoxic evaluation, and molecular docking studies of novel quinazoline derivatives with benzenesulfonamide and anilide tails: Dual inhibitors of EGFR/HER2

(2019) Hamad M. Alkahtani et al.   BIOORGANIC CHEMISTRY

Dual EGFR/HER2 inhibitors and apoptosis inducers: New benzo[ g ]quinazoline derivatives bearing benzenesulfonamide as anticancer and radiosensitizers

(2018) Mostafa M. Ghorab et al.   BIOORGANIC CHEMISTRY

Discovery of new quinazoline derivatives as irreversible dual EGFR/HER2 inhibitors and their anticancer activities – Part 1

(2018) Debasis Das et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Discovery of Benzo[g]quinazolin benzenesulfonamide derivatives as dual EGFR/HER2 inhibitors

(2017) Mansour S. Alsaid et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of N -(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC

(2017) Yongfei Chen et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer

(2017) Xin Li et al.   EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES

Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors

(2017) Mostafa M. Ghorab et al.   JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY

The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer

(2016) Jennifer L. Hsu et al.   CANCER AND METASTASIS REVIEWS

Design, synthesis and biological evaluation of novel EGFR/HER2 dual inhibitors bearing a oxazolo[4,5-g]quinazolin-2(1H)-one scaffold

(2016) Siyuan Yin et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy

(2015) Elias E. Stratikopoulos et al.   CANCER CELL

Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab

(2015) S. Napolitano et al.   CLINICAL CANCER RESEARCH

Design and synthesis of Lapatinib derivatives containing a branched side chain as HER1/HER2 targeting antitumor drug candidates

(2014) Aifeng Lyu et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

c-Met Targeting Enhances the Effect of Irradiation and Chemical Agents against Malignant Colon Cells Harboring a KRAS Mutation

(2014) Yingbo Li et al.   PLoS One

Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors

(2013) Maria Letícia de Castro Barbosa et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer

(2011) S. Iqbal et al.   ANNALS OF ONCOLOGY

Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models

(2011) M. P. Morelli et al.   CLINICAL CANCER RESEARCH

A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer

(2010) Srikala S. Sridhar et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer

(2010) H. J. Ross et al.   CLINICAL CANCER RESEARCH

A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

(2009) K.-K. Wong et al.   CLINICAL CANCER RESEARCH

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38

(2009) Melissa J. LaBonte et al.   INTERNATIONAL JOURNAL OF CANCER

EGFR and colon cancer: a clinical view

(2008) Javier de Castro-Carpeño et al.   Clinical & Translational Oncology

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

(2008) M Hofmann et al.   HISTOPATHOLOGY